Replies to post #22008 on Marijuana - Public Weed Stocks & Analysis (WEED)

[Sobek]

$AMFE DD on GroZone MMJ and S&L Acquisition

Now generating an estimated $2-$3 MILLION IN ADDITIONAL ANNUAL REVENUE to be reflected in their Q2 financials (their Q2 ends December 31st) as announced back on Sept 28th and just released updates on November 16th.

November 16th news

OTC Pink Current / Updated Share Structure

As of November 16th
Outstanding 741,000,000
Float 193,000,000
CEO Owned 350,000,000
Restricted Shares est. at 445,000,000 including the CEO’s.

*NO TOXIC FINANCING*

The company has for the vast majority always funded in-house so to speak through friends, family and close friendly shareholders and has never in the past or will in the future sign a toxic financing deal which is one of the major contributing factors to our public float being 192,859,481 which is cumulative since the company's inception in 1985.

*ONLY $494,000 IN LIABILITIES OF WHICH $240,000 IS OWNED BY MANAGEMENT*

Of the $494,297 in remaining liabilities, $239,171 is loans from management to the company and non interest bearing, sales tax payable of which the vast majority has been paid off in Q2, accounts payable and accrued liabilities from ongoing day to day business and prior audit fees which a large portion has been paid and will continue to be paid throughout Q2 as well as a convertible note to a family member of management and two long standing shareholders of the company.

*RECENT DEBT REDUCTION*

Our outstanding share count and public float with the DTC did see a slight increase this quarter to 741,043,098 and 192,859,481 respectively. This was attributable to a combination of debt reduction mostly related to audit/accounting costs, long standing funders who believe in the company's success and the acquisition (bearing restrictive legend). This is quite rare for our company to anyone that has been following for some time but was necessary to help clean up some overhanging debt and help our positioning moving forward.

*RECENT ACQUISITION ALREADY BRINGING IN AN ESTIMATED $2 TO $3 MILLION IN ANNUAL REVENUES*

Revenues from this subsidiary (Snakes & Lattes) will begin to be reflected on our Q2 2016 financial statement. As stated previously we estimate approx. $2M - $3M in additional yearly revenues from this subsidiary and is very likely to be much higher in the future as current deals in progress and planned expansion comes to fruition.

*Snake & Lattes ALREADY WORKING ON THREE ADDITIONAL LOCATION FRANCHISES*

The first goal of Amfil Technologies Inc. with regards to the recent acquisition is to assist and help support the team in place open an additional three Snakes & Lattes locations to add under the umbrella. We are currently and will be in the near future working on finalizing the franchising agreements so future would-be owners can gain access to the brand and help an exponential expansion. The company has been contacted by various potential candidates from all across North America looking to get into the business and wanting to purchase a franchise.

*GroZone RAMPING UP FULL TIME EXPERIENCED SALES FORCE TO MEET DEMAND POTENTIAL*

As for the GROzone initiative, the company has been in discussions with highly qualified individuals who could be very capable marketers and lead generators for the GROzone product line. Previously while the company was having success with the technology and the GROzone 60 system, we lacked a proper sales network for the product and being able to showcase the positives the technology brought to the industry. Having marketers of the products focusing 100% of their time and effort into a space that they know, understand and are comfortable in we feel will lead to increasing sales for the subsidiary. North America has been pushing closer and closer towards full "Medical Marijuana" acceptance with there now being 36 licensed producers in Canada and with 26 states and the district of Columbia having legalized marijuana in some form. Three additional states appears will soon join that list and therefore while some would say we started early on this product, we feel we are ahead of the game and will need to use this to our advantage now to capitalize on this growth for the good of the GROzone venture.

More information on company owned subsidiaries

1). System and service provider to medicinal marijuana industry
The Company has entered into a Joint Venture Agreement to acquire 50% ownership in the mPact GROZONE Antimicrobial Systems and worldwide exclusive distribution rights. A.C.T.S. Inc. is a systems and service manufacturer of mPact GROZONE Antimicrobial Systems which is an exclusive application specifically designed to meet the needs ofthe marijuana industry, including marijuana cultivation and extractor edible processing facilities. The mPact GROZONE Antimicrobial Systems was developed from the existing mPact technology which services primarily the food and beverage industry and has successfully installed numerous high performing units in the Food/Beverage and Fresh Produce Industries with clients such as Sysco Foods, Nestles, Sun Pacific, Thornbury Apple Cidery, etc.

http://grozone.biz/



2). Landscape construction and snow removal services
InterlocKings Inc. was incorporated in the Province of Ontario in April 2009 and was 100% owned by Roger Mortimer. Over the last four years, clients and revenues have consistently increased. The business leases many trucks, tools, machinery and equipment to facilitate the growing business all while paying the employees and owner salaries and having no outside funding or capital ever injected into the business.

http://www.interloc-kings.com/



3). Recently acquired Snakes & Lattes & Lagers
Amfil Technologies Inc. (AMFE) anticipates a conservative estimate of $2-$3 Million of immediate annual revenue which will be reflected on the Q2 financials (March 2017). Further to the popularity of the current Snakes & Lagers locations and online sales, Amfil Technologies Inc. has received a great deal of interest from entrepreneurs throughout North America, looking to purchase Snakes & Lattes franchises since the release of the LOI in April 2016. Amfil Technologies Inc. anticipates the revenue estimates of $2-$3 Million to grow considerably through the expansion of the retail, online and franchise divisions.

Snakes & Lattes offers a full menu of food & drink alongside a library full of games. Delivered by savvy baristas, creative bartenders, a talented kitchen staff, and table side service, the staff are available to help guests not only by making suggestions of the menu but also of the games. A $5 admission provides access to a public library of games, with a diversity from the classics to the modern, from dexterity to trivia, from strategy to party. Whether you come for a thirty-minute Jenga duel or for an afternoon of Eldritch Horror, Snakes & Lattes is happy to host you.

Guests can choose and play any number of the available titles that pique their interest. If picking a game ever feels like a daunting proposition, guests can invite the services of a game guru: mystical, benevolent beings that Snakes & Lattes employs to recommend and teach games.

Beyond the menu and the games libraries, Snakes & Lattes also offers a vast retail selection, whether you prefer to shop in store with the help of our staff or online with free Canadian shipping.

http://www.snakesandlattes.com/





Following pics taken with great thanks by ihub member antman at Snakes & Lattes's 489 College Street location in Toronto.











LATEST NEWS

Amfil Technologies Inc. Files Q1 2016 and Provides Shareholder Update
http://www.otcmarkets.com/stock/AMFE/news/Amfil-Technologies-Inc--Files-Q1-2016-and-Provides-Shareholder-Update?id=145000&b=y

Amfil Technologies Inc. Closes Acquisition of Snakes & Lagers Inc.
https://www.accesswire.com/viewarticle.aspx?id=446126

Amfil Technologies Inc. Signs L.O.I. to Acquire Snakes & Lagers Inc; Anticipates $2 Million - $3 Million in Additional Annual Revenue
http://www.otcmarkets.com/stock/AMFE/news/Amfil-Technologies-Inc--Signs-L-O-I--to-Acquire-Snakes--amp--Lagers-Inc--Anticipates--2-Million----3-Million-in-Additional-Annual-Revenue?id=128664&b=y


Corporate Website
http://www.amfiltech.com


https://www.barchart.com/stocks/quotes/AMFE/overview

[MasterBlastr]

What are your thought on NMUS now - chart has reset, O/S still under 21 million, small float, could start again.

[High_Profits]

TOP MJ PICK for 2017 = $OWCP [ OTC:OWCP ]
http://www.topcannabisstock.com/index.php/our-top-cannabis-stock/

Our Top Cannabis Stock
For many reasons, our top cannabis stock pick for 2017 is OWC Pharmaceutical Research Corp (OTC QB: OWCP).

Here’s our list of reasons as to why we feel OWCP will be the cannabis stock of 2017:

follow OWCP on Twitter
https://twitter.com/OWCPharma

Market Value: With a low $24 million Market Cap (as of January 1, 2017), they’re have tons of room for growth. We feel they’re so undervalued because they are still pre-revenue. But, that changes in Quarter 2 of 2017.

OTC QB, not Pink Sheets. Most people who are making an investment (not flipping) are usually uncomfortable with Pink Sheet stocks. To see the list of requirements and understand the line of thinking here, check out OTCmarkets.com.

Share Structure: The outstanding share count is 139,255,474 as of January 1, 2017. There’s a couple of cannabis sector stocks trading on the Pink Sheets with 2.3 BILLION outstanding shares
No Toxic Debt: Again, unlike many Pink Sheet companies — OWCP has no convertible notes whatsoever. Instead, they have non-interest bearing financing.

Distribution & Manufacturing Deals: Back in March 2016, they announced a manufacturing deal with Emilia Cosmetics, one of Israel’s largest private label cosmetics companies. In September 2016, OWCP got a $300,000 deal with MedMar for distribution in the USA. Then, in November 2016, OWCP announced a $300,000 deal with Michepro to promote, market, sell, and distribute products throughout Europe for a 25% cut.
Real Doctor(s): Dr. Yehuda Baruch, MD is a real doctor who was the head of the Israeli Medical Use of Cannabis Programme from 2003 – 2012. Read more from the Medical Cannabis Conference website.

Products to Launch: You can see on ClinicalTrails.gov
https://clinicaltrials.gov/ct2/show/NCT02976779
that there really is an ongoing study. On October 11th, 2016, they announced the Final Phase for Testing of their Psoriasis Cream. Then, on October 20th, 2016, they announced the completed development of a Medical Cannabis Sublingual Tablet — a smoke-free alternative.

Expert Advisors: OWCP has brilliant industry advisors like Jeffrey Friedland, who wrote the book “Marijuana: The World’s Most Misunderstood Plant“.

Provisional Patents: OWCP has EIGHT provisional patents with the United States Patent and Regulatory Office (USPTO), all related to its line of activity related to cannabis-based medical products.

Acquisition Offer: TEVA, a 115 year old pharmaceutical company with over $20 billion in revenue, made an offer to purchase OWCP’s patents! This leads me to believe there will be future offers as OWCP continues to advance their research and get closer to shipping products worldwide!

Comparison: Simply compare GWPH to OWCP. That’s exactly what OWCP can become later this year. Want to be conservative? If OWCP grows to 1/3rd of GWPH’s Market Value, they’ll be trading around $7.18/share. The reason we feel this is realistic? GWPH has only one FDA approved product thus far. OWCP could easily have two (or more) out by the end of 2017.

We’ll see how things continue to unfold, but there’s no reason not to think big things are going to happen for OWCP in 2017.